Guidelines and tumor boards are required for solid organ recipients with de novo carcinoma

Oncotarget. 2019 Apr 19;10(29):2789-2790. doi: 10.18632/oncotarget.26860.

Authors

Benoit Rousseau¹, Aude Guillemin¹, Christophe Tournigand¹

Affiliation

¹ Benoit Rousseau: Department of Medicine, Solid Tumor Division, Mortimer B. Zuckerman Research Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Medical Oncology, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France; University of Paris-Est, Faculty of Medicine, Créteil, France.

No abstract available

Keywords: cancer; guidelines; mTOR inhibitors; prognosis; transplantation.

Publication types

Editorial